What Hormone Therapy Actually Is
Hormone therapy (HT) — sometimes called menopausal hormone therapy or MHT — refers to the use of estrogen, often combined with progestogen, to supplement the hormones the ovaries produce in smaller amounts after menopause. Estrogen-only therapy is generally reserved for women who have had a hysterectomy; those with a uterus typically use a combination form to protect the uterine lining.
HT comes in several forms: pills, skin patches, gels, creams, and vaginal preparations. These differ not only in delivery route but in how hormones are absorbed and distributed in the body — a distinction that can matter for both effectiveness and risk. For a broader view of how hormonal shifts affect overall wellbeing, see our guide to lifestyle habits that support hormonal balance.
Bioidentical Hormones: A Note on Terminology
The term 'bioidentical hormones' is widely used in marketing but can be misleading. FDA-approved hormone therapies that are chemically identical to the body's own hormones exist and are well-studied. Compounded 'bioidentical' preparations, however, are not held to the same regulatory standards and lack the same evidence base. If you've heard this term, it's worth discussing the distinction with your healthcare provider.
The Case For: Key Benefits of Hormone Therapy
For women navigating the disruptive symptoms of menopause, HT offers real, well-documented relief. Understanding the specific benefits helps frame why many healthcare providers still consider it a first-line option for appropriate candidates.
Effectively reduces hot flashes and night sweats
Estrogen therapy is the most effective available treatment for vasomotor symptoms, which affect up to 80% of women during menopause. Many women experience a significant reduction in frequency and severity within weeks of starting treatment.
Supports bone density and reduces fracture risk
Estrogen plays a key role in maintaining bone mineral density. HT has been shown to reduce the risk of osteoporotic fractures, including hip fractures, in postmenopausal women — a meaningful benefit given that bone loss accelerates rapidly after menopause.
Relieves genitourinary symptoms of menopause
Vaginal dryness, discomfort during intercourse, and urinary urgency are common and often underreported symptoms. Local or systemic estrogen therapy can meaningfully improve these genitourinary symptoms, supporting quality of life and sexual health.
May lower risk of type 2 diabetes
Some evidence suggests that HT may improve insulin sensitivity and reduce the incidence of type 2 diabetes in postmenopausal women, though this is considered a secondary finding and not a primary reason to initiate treatment.
May reduce colorectal cancer risk
Combined estrogen-progestogen therapy has been associated in some studies with a modestly reduced risk of colorectal cancer, though the mechanisms are not fully understood and this benefit must be weighed against other risks.
~75%
Women who experience vasomotor symptoms in menopause
Estimates from multiple epidemiological studies suggest the majority of women experience hot flashes or night sweats, with a significant proportion describing them as moderate to severe.
Up to 34%
Reduction in hip fracture risk with HT
The Women's Health Initiative reported a statistically significant reduction in hip fracture incidence among HT users compared with placebo in their study population.
The Case Against: Risks Worth Understanding
No treatment is without tradeoffs, and HT is no exception. The risks below are drawn from established research, including large-scale studies such as the Women's Health Initiative (WHI). Importantly, the WHI studied one specific oral combination HT regimen in an older postmenopausal population — results do not automatically translate to all forms, doses, or timings of HT. For a deeper look at how hormone exposure relates to cancer risk more broadly, see hormone exposure and cancer risk.
Associated with increased breast cancer risk with long-term use
Combined estrogen-progestogen therapy is associated with a small but real increase in breast cancer risk, particularly with use extending beyond five years. Estrogen-only therapy in women without a uterus appears to carry a lower or neutral breast cancer risk, but monitoring remains important.
Elevated risk of blood clots with oral forms
Oral estrogen has been linked to an increased risk of venous thromboembolism (blood clots in the veins). Transdermal formulations — patches, gels — appear to carry a lower clot risk, though individual health factors always apply.
Not appropriate for women with certain medical histories
HT is generally contraindicated for women with a personal history of hormone-sensitive cancers (such as some breast or uterine cancers), unexplained vaginal bleeding, active liver disease, or a prior blood clot or stroke. These exclusions are clinically significant.
Possible increased risk of stroke with oral therapy
Oral estrogen has been associated with a modestly elevated stroke risk in some studies, particularly in older postmenopausal women. Again, transdermal routes appear to have a more favorable safety profile in this regard.
Symptoms may return after stopping treatment
Hot flashes and other vasomotor symptoms can recur when HT is discontinued, sometimes quite abruptly. Tapering and transition planning should be discussed with a provider rather than stopping suddenly.
The Timing Hypothesis: Why When You Start Matters
One of the most important developments in HT research is what clinicians call the timing hypothesis — the idea that starting HT closer to the onset of menopause (generally within 10 years or before age 60) may be associated with greater cardiovascular benefit and a more favorable overall risk profile compared with starting it later.
Studies suggest that estrogen may have protective effects on blood vessels when initiated during a window of early menopause, but may have neutral or adverse effects when begun in women who are significantly older or many years past their final period. This does not mean HT is risk-free for early initiators, but it does underscore that timing is a meaningful variable — one your healthcare provider should factor into any shared decision-making conversation.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about hormone therapy or any other medical treatment.
